Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVMNASDAQ:GRNANASDAQ:JNCENASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$2.71-3.6%$3.87$2.64▼$10.14$56.62M1.03270,584 shs621,160 shsGRNAGreenLight Biosciences$0.30$0.30$0.18▼$5.90$45.43M1.44486,986 shs732 shsJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsTILInstil Bio$13.68+3.4%$16.28$9.62▼$92.00$89.73M1.78132,599 shs73,148 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies0.00%-19.77%-18.37%-36.94%-69.89%GRNAGreenLight Biosciences0.00%0.00%0.00%0.00%0.00%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%TILInstil Bio0.00%-9.25%-12.57%-34.37%+13.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.0525 of 5 stars3.42.00.04.82.02.50.6GRNAGreenLight BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATILInstil Bio3.3938 of 5 stars3.52.00.00.03.83.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.80Moderate Buy$26.60881.55% UpsideGRNAGreenLight Biosciences 0.00N/AN/AN/AJNCEJounce Therapeutics 0.00N/AN/AN/ATILInstil Bio 3.00Buy$114.00733.33% UpsideCurrent Analyst Ratings BreakdownLatest JNCE, ADVM, GRNA, and TIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $33.004/16/2025ADVMAdverum BiotechnologiesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$10.00 ➝ $5.004/16/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $110.002/13/2025TILInstil BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M56.61N/AN/A$8.26 per share0.33GRNAGreenLight Biosciences$10.20M4.45N/AN/A$0.32 per share0.94JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53TILInstil BioN/AN/AN/AN/A$34.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$5.65N/AN/AN/AN/A-65.14%-40.52%N/AGRNAGreenLight Biosciences-$167.05M-$1.14N/A∞N/A-1,521.00%-374.26%-122.78%N/AJNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/ATILInstil Bio-$156.09M-$11.39N/AN/AN/AN/A-37.44%-25.08%N/ALatest JNCE, ADVM, GRNA, and TIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2025Q4 2024ADVMAdverum Biotechnologies-$1.34-$1.96-$0.62-$1.96N/AN/A3/4/2025Q4 2024TILInstil Bio-$3.75-$1.82+$1.93-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AGRNAGreenLight BiosciencesN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A5.825.82GRNAGreenLight Biosciences0.491.211.21JNCEJounce TherapeuticsN/A8.378.37TILInstil Bio0.4712.9012.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%GRNAGreenLight Biosciences24.41%JNCEJounce Therapeutics80.66%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies4.20%GRNAGreenLight Biosciences30.30%JNCEJounce Therapeutics6.92%TILInstil Bio47.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.89 million19.93 millionOptionableGRNAGreenLight Biosciences280151.68 million105.72 millionNot OptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionableTILInstil Bio4106.56 million3.49 millionNo DataJNCE, ADVM, GRNA, and TIL HeadlinesRecent News About These CompaniesInstil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last yearMarch 4, 2025 | markets.businessinsider.comInstil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 4, 2025 | globenewswire.comInstil Bio: Time To Hop On The Summit Wave?February 24, 2025 | seekingalpha.comPrivate equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as wellFebruary 20, 2025 | finance.yahoo.comJMP Securities Keeps Their Hold Rating on Instil Bio (TIL)February 13, 2025 | markets.businessinsider.comSummit Therapeutics (NASDAQ:SMMT) Stock Quotes, Forecast and News SummaryJanuary 24, 2025 | benzinga.comInstil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific AntibodyJanuary 14, 2025 | globenewswire.comInstil Bio upgraded to Buy from Hold at JefferiesJanuary 7, 2025 | markets.businessinsider.comJefferies Upgrades Instil Bio (TIL)January 7, 2025 | msn.comInstil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail JubilantJanuary 7, 2025 | msn.comInstil Bio Secures Loan to Refinance FacilityDecember 23, 2024 | tipranks.comCautious Hold Rating for Zura Bio Amid Efficacy Concerns and Licensing ChallengesNovember 18, 2024 | markets.businessinsider.comStrategic Acquisitions and Market Potential Position Instil Bio’s SYN-2510 as a Buy with High Growth ProspectsNovember 18, 2024 | markets.businessinsider.comInstil Bio price target lowered to $110 from $120 at H.C. WainwrightNovember 15, 2024 | markets.businessinsider.comInstil Bio Poised for Growth Amid Biopharmaceutical Sector Activity and Strong Financial PositionNovember 15, 2024 | markets.businessinsider.comMerck to buy rights to Chinese cancer drug for up to $3.3BNovember 14, 2024 | msn.comInstil Bio (TIL) Gets a Hold from JMP SecuritiesNovember 14, 2024 | markets.businessinsider.comInstil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | manilatimes.netInstil Bio initiated with a Market Perform at JMP SecuritiesNovember 5, 2024 | markets.businessinsider.comJMP Securities Initiates Coverage of Instil Bio (TIL) with Market Perform RecommendationNovember 5, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJNCE, ADVM, GRNA, and TIL Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$2.71 -0.10 (-3.56%) Closing price 04:00 PM EasternExtended Trading$2.78 +0.08 (+2.77%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.GreenLight Biosciences NASDAQ:GRNAFUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.Jounce Therapeutics NASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Instil Bio NASDAQ:TIL$13.68 +0.45 (+3.40%) Closing price 04:00 PM EasternExtended Trading$13.74 +0.06 (+0.48%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
